Ces radiol. 2021, 75(1):31-44 | DOI: 10.55095/CesRadiol2021/003

Imaging of the prostatic carcinoma using PET/CT and PET/MRI with the application of 68Ga-PSMA-11Original article

Jiří Ferda1, Eva Ferdová1, Jan Pernický1, Marika Looseová1, Martina Odvody1, Milan Hora2, Jindřich Fínek3, Ondřej Topolčan4, Ladislav Pecen4, Ondřej Hes5
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Urologická klinika LF UK a FN, Plzeň
3 Onkologická a radioterapeutická klinika LF UK a FN, Plzeň
4 Oddělení imunodiagnostiky LF UK a FN, Plzeň
5 Šiklův ústav patologické anatomie LF UK a FN, Plzeň

Aim: To assess the experience with the PET/MRI and PET/CT with the application of 68Ga-PSMA-11 in patients with diagnostics of prostatic carcinoma, the assessment targeted the logistic, safety, and the inclusion of 68Ga-PSMA-11 into the diagnostic work-up.

Method: 500 examinations with the application of 68Ga-PSMA-11 were performed between January 2018 and December 2020, there were 200 of PET/CT and 300 of PET/MRI in 449 male patients, in 43 of them were performed multiple examinations. 68Ga-PSMA-11 into was injected using activity dosing of 1.25 MBq per kilogram of body weight. PET/CT examinations were performed in the extent of trunk and head except those indicated to radioligand therapy or biochemical relapse, when it was used the whole-body examination. In PET/MRI, the targeted pelvic imaging was performed before the trunk and head examinations, with the exception of cases when the radical prostatectomy was used, then the targeted examination was targeted.

Results: No serious complication related to the application of 68Ga-PSMA-11 were registered. In PET/CT, the most frequent indication was restaging during therapy (53%, 106 cases), followed by the staging examination (31%, 62 examinations), in opposite PET/MRI was indicated most often due to the staging (67%, 201 examinations), restaging in 20% (60 examinations), respectively. The ration of particular examinations and also percentage was almost equal in indication of biochemical relapse (PET/CT in 22 cases, 11%, PET/MRI in 8%, 24 examinations).

Conclusion: 68Ga-PSMA-11 is safe and valuable radiopharmaceutical in staging, restaging and assessment of the therapy response in patients with prostatic carcinoma. When the availability of PET/CT and PET/MRI is the equal, PET/MRI is preferred in staging of the disease, in opposite side, PET/CT in the assessment of the effect of therapy or restaging.

Keywords: 68Ga-PSMA-11, PET/MRI, PET/CT, prostatic carcinoma
Grants and funding:

Podpořeno projektem MZ ČR Koncepčnî rozvoj výzkumné instituce 00669806 - FN Plzeň a projektem Univerzity Karlovy v Praze Progress q39.

Accepted: March 3, 2021; Published: March 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Ferdová E, Pernický J, Looseová M, Odvody M, Hora M, et al.. Imaging of the prostatic carcinoma using PET/CT and PET/MRI with the application of 68Ga-PSMA-11. Ces radiol. 2021;75(1):31-44. doi: 10.55095/CesRadiol2021/003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alberts IL, Seide SE, Mingels C, et al. Comparing the diagnostic performance of radiotracers inrecurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging 2021 Feb 6. doi: 10.1007/s00259-021-05210-9 [Epub ahead of print]. Go to original source... Go to PubMed...
    2. Kuten J, Fahoum I, Savin Z, et al. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med 2020; 61(4): 527-532. Go to original source... Go to PubMed...
    3. Satapathy S, Singh H, Kumar R, Mittal BR. Diagnostic Accuracy of 68Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis. Am J Roentgenol 2021; 216(3): 599-607. Go to original source... Go to PubMed...
    4. Hoffmann MA, Buchholz HG, Wieler HJ, et al. Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patientswith Biochemical Recurrence of Prostate Carcinoma. Health Phys 2020; 119(1): 141-147. Go to original source... Go to PubMed...
    5. Guberina N, Hetkamp P, Ruebben H, et al. Whole-Body Integrated 68GaPSMA-11-PET/MRI maging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference. Mol Imaging Biol 2020; 22(3): 788-796. Go to original source... Go to PubMed...
    6. Emmett L, Metser U, Bauman G, et al. Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. J Nucl Med 2019; 60(6): 794-800. Go to original source... Go to PubMed...
    7. Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA < 0.5 ng/ml. Efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging 2019; 46(1): 11-19. Go to original source... Go to PubMed...
    8. Emmett L, Yin C, Crumbaker M, et al. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. J Nucl Med 2019; 60(7): 950-954. Go to original source... Go to PubMed...
    9. Kesler M, Druckmann I, Levine C, et al. 68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy. Diagnostics (Basel) 2021; 11(2): 277-282. Go to original source... Go to PubMed...
    10. Damjanovic J, Janssen JC, Prasad V, et al. 68Ga-PSMA-PET/CT for the evaluation of liver metastasesin patients with prostate cancer. Cancer Imaging 2019; 19(1): 37. doi: 10.1186/s40644-019-0220-x. PMID: 31186052; PMCID: PMC6560719. Go to original source... Go to PubMed...
    11. Schmidt Hegemann NS, Rogowski P, Eze C, et al. Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. Cancers (Basel) 2020; 12(11): 3395. doi: 10.3390/cancers12113395 Go to original source... Go to PubMed...
    12. Uprimny C, Svirydenka A, Fritz J, et al. Comparison of 68Ga-PSMA-11 PET/CT with 18FNaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Eur J Nucl Med Mol Imaging 2018; 45(11): 1873-1883. Go to original source... Go to PubMed...
    13. Maurer T, Gesterkamp H, Nguyen N, et al. 68Ga-PSMA-11 PET/mpMRT zur Lokal detektiondes primären Prostatakarzinom bei Männern mit negativer Vorbiopsie [68Ga-PSMA-11 PET/mpMRI for local detection of primary prostate cancer in men with a negativeprior biopsy]. Aktuelle Urol 2020 Aug 27. German. doi: 10.1055/a-1198-2305 [Epub ahead of print]. PMID: 32854128. Go to original source... Go to PubMed...
    14. Hicks RM, Simko JP, Westphalen AC, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology 2018; 289: 730-757. Go to original source... Go to PubMed...
    15. Muehlenmatter UJ, Burger IA, Becker AS, et al. Diagnostic accuracy of multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. Radiology 2019; 293: 350-358. Go to original source... Go to PubMed...
    16. Olde Heuvel J, de Wit-van der Veen BJ, Sinaasappel M, Slump CH, Stokkel MPM. Early differences in dynamic uptake of 68Ga-PSMA-11 in primary prostate cancer: A test-retest study. PLoS One 2021; 16(2): e0246394. doi: 10.1371 Go to original source... Go to PubMed...
    17. Muehlematter UJ, Rupp NJ, Mueller J, Eberli D, Burger IA. 68Ga-PSMA PET/MR-Positive, Histopathology-Proven Prostate Cancer in a Patient With Negative Multiparametric Prostate MRI. Clin Nucl Med 2018; 43(8): e282-e284. doi: 10.1097/RLU.0000000000002143 Go to original source... Go to PubMed...
    18. Petersen LJ, Nielsen JB, Langkilde NC, et al. 68Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. World J Urol 2020; 38(4): 939-948. Go to original source... Go to PubMed...
    19. Ferraro DA, Rupp NJ, Donati OF, et al. 68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue. Clin Nucl Med 2019; 44(4): e291-e293. doi: 10.1097/RLU.0000000000002473 Go to original source... Go to PubMed...
    20. Nandurkar R, van Leeuwen P, Stricker P, et al. 68Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery. Br J Radiol 2019; 92(1095): 20180667. doi: 10.1259/bjr.20180667 [Epub 2019 Jan 23]. Go to original source... Go to PubMed...
    21. Schweighofer Zwink G, Rendl G, Schmeller N, Pirich C. Para-aortal Ganglion Mimicking a Lymph Node Metastases on 68Ga-PSMA PET/CT. Clin Nucl Med 2020; 45(11): 883-885. doi: 10.1097/RLU.0000000000003247 Go to original source... Go to PubMed...
    22. Engur CO, Turoglu HT, Ozguven S, Tanidir Y, Erdil TY. 68Ga-Prostate-Specific Membrane Antigen PET-Positive Paget Bone Disease With Metastatic Prostatic Carcinoma. Clin Nucl Med 2020; 45(9): e425-e426. doi: 1097/RLU.0000000000003198 Go to original source... Go to PubMed...
    23. Schiller K, Devecka M, Maurer T, et al. Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer. Radiat Oncol 2018; 13(1): 36. doi: 10.1186/s13014-018-0977-2 Go to original source... Go to PubMed...
    24. Kalinauskaite G, Senger C, Kluge A, et al. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer. PloS One 2020; 15(10): e0240892. doi: 10.1371/journal.pone.0240892 Go to original source... Go to PubMed...
    25. Wangerin K, Iagaru A. Improved Scatter Correction to Eliminate Halo Artifacts for 68Ga-Labeled Radiopharmaceuticals in PET Imaging. J Nucl Med 2019; 60(9): 1334. doi: 10.2967/jnumed.119.230557 [Epub 2019 May 10]. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content